Research Background

Selank: Background on a Tuftsin-Analog Research Peptide

A factual overview of the origin, structure, and laboratory research context of the synthetic heptapeptide Selank.

Published 2026-06-11 · 5 min read

Introduction

Selank is a synthetic heptapeptide that appears in neuropharmacology and immunology research literature. This article provides a factual overview of its origin, structure, and the laboratory research context in which it is studied. It is intended solely as a research reference and makes no statement regarding use in humans or animals.

Origin

Selank was developed by Russian research groups as a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the heavy chain of immunoglobulin G. The native sequence is extended with a C-terminal Pro-Gly-Pro motif that the literature associates with improved resistance to enzymatic degradation under laboratory conditions. It is frequently discussed alongside Semax, another short regulatory peptide from the same research tradition.

Structure

The reported sequence of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, with a molecular weight near 751.9 g/mol. The C-terminal Pro-Gly-Pro extension is the structural feature most often highlighted in analytical discussions of the molecule's stability relative to the parent tuftsin fragment in vitro.

Laboratory Research Context

In the research literature, Selank is examined as a tuftsin analog in both neuropharmacological and immunological model systems. Areas that published authors have investigated include the following, listed for reference only and without any implication of effect:

  • Expression of genes involved in GABAergic neurotransmission in cultured-cell and laboratory-model studies.
  • Tuftsin-related modulation of inflammation-associated gene expression examined in vitro.
  • Comparative connectomic and signaling studies conducted alongside the related peptide Semax.

Analytical Characterization

Research-grade Selank is supplied lyophilized and characterized by reversed-phase HPLC for purity, with identity confirmed by mass spectrometry. FYH Peptides documents batch-specific HPLC purity on each Certificate of Analysis. The lyophilized peptide is handled following standard laboratory practice, including storage at −20 °C away from light and moisture.

Summary

Selank is a synthetic tuftsin-analog heptapeptide referenced in in vitro and laboratory-model neuropharmacology and immunology research. The content above is a neutral research reference and does not describe or support any application in humans or animals.

Referenced research compound Selank 10mg · 99.92% HPLC View compound data →

Published Research

Selected peer-reviewed literature indexed on NCBI PubMed. Listed for laboratory reference only — FYH Peptides makes no claim regarding the conclusions of any cited author.

  1. 1. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 PubMed · DOI
  2. 2. Tuftsin - Properties and Analogs. Siebert A, Gensicka-Kowalewska M, Cholewinski G, et al. · Current medicinal chemistry · 2017 PubMed · DOI
  3. 3. Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress. Fomenko EV, Bobyntsev II, Ivanov AV, et al. · Bulletin of experimental biology and medicine · 2019 PubMed · DOI
  4. 4. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Konstantinopolsky MA, Chernyakova IV, Kolik LG · Bulletin of experimental biology and medicine · 2022 PubMed · DOI
  5. 5. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Kolomin T, Morozova M, Volkova A, et al. · Molecular immunology · 2014 PubMed · DOI
For Research Use Only. This article is a neutral laboratory reference. It does not describe, recommend, or imply use of any compound in humans or animals, and is not medical, therapeutic, or dietary guidance. The FDA has not evaluated any compound discussed for safety or efficacy.